VentfortВентфорт
A peptide mixture extracted from animal aorta, described in Russian reports on blood vessels and in dental patent cases.
What the studies found
Comparison in people · 2006
Ventfort: clinical report on a tissue-derived preparation
The 2005–2006 report describes lipid and capillary-fragility outcomes during 10–15 days of adjunctive care.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 49 patients: 27 adjunctive Ventfort; 22 controls; ages 52–84, atherosclerosis or senile purpura.
Important limitations
- The table contains inconsistent sex subtotals. Lipid-table significance is relative to baseline; it does not establish fewer cardiovascular events. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date · Institute report — commercial reproduction
Comparison in people · 2021
Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration
Study of multiple preparations
- Visual acuity
- Retinalamin alone 0.71 ± 0.05 to 0.76 ± 0.04. Combination 0.76 ± 0.05 to 0.88 ± 0.04.
- Electroretinogram a-wave amplitude
- Retinalamin alone 21.2 ± 1.5 to 28.1 ± 1.7 µV. Combination 21.4 ± 1.5 to 33.9 ± 1.5 µV.
- Electroretinogram b-wave amplitude
- Retinalamin alone 173.7 ± 8.1 to 222.7 ± 6.6 µV. Combination 172.8 ± 8.6 to 250.0 ± 7.3 µV.
Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.
Study notes · methods, sources and limitations
Participants or model 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
Design Five courses, repeated one to two times per year. The methods list temporal paravascular Retinalamin 5 mg daily for 10 days in both groups. In the combination group, Cortexin and Ventfort Lingval were given by cathodal drug electrophoresis daily for five days, 20 minutes per session at up to 0.1 mA/cm². Active mass for the two electrophoresis preparations was unspecified.
Important limitations
- The report gives no randomization or masking method and the groups start with different acuity values. The contribution of each added preparation and electrophoresis cannot be isolated. The methods name Retinalamin but also describe Retilin in the adjacent text. The authors leave the mass applied by electrophoresis unspecified. The narrative percentages lack clear denominators. The tables contain no between-group p values or confidence intervals. Independent overlap with other retina cohorts is unspecified.
- The combination adds two preparations and a different procedure. The report supplies no treatment-specific estimate for Cortexin or Ventfort Lingval and no between-group confidence intervals.
Vrach. 2021;32(5):85–87. · Original journal report
Comparison in people · 2013
Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis
Study of multiple preparations
- Total cholesterol
- 7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4.Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable.
- VLDL cholesterol
- 1.22 ± 0.06, 0.92 ± 0.07 and 0.87 ± 0.05 mmol/L, respectively. Shared baseline 1.42 ± 0.07.Both adjunctive groups are marked significant versus standard care.
- Reported fatigue
- 64.0%, 32.3% and 12.9%, respectively. Shared baseline 75.6%.Only the four-product group is marked significant versus standard care in the fatigue row.
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.
Study notes · methods, sources and limitations
Participants or model 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
Design Moscow, December 2011 to June 2012. Standard treatment alone (514), with Ventfort and Cerluten (319), or with those two plus Svetinorm and Endoluten (416). The Russian methods list two oral capsules each per day for three months for Ventfort, Cerluten and Svetinorm when assigned. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified.
Important limitations
- The authors excluded statin users and people with prior stroke. The comparison provides no individual estimates for Svetinorm or Endoluten. Both editions name Svetinorm in the four-product group and outcome tables. The English dosing list instead says Suprefort. The schedule below follows the Russian methods. The table gives one shared pretreatment column. Methods of allocation and masking, timing of the reported tables and adverse-event ascertainment are unspecified. Table 1 repeats the triglyceride heading with values of unclear identity. The cholesterol, VLDL and first triglyceride rows are legible. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
- The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. Symptom assessment and statistical methods are incompletely reported. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides. · Conference report · company reproduction
About Ventfort
Identity / background source ↗
Research background
Ventfort is a vascular tissue peptide preparation studied for blood lipids, capillary fragility and urinary symptoms. The prostate study used a combination of preparations.
More study findings
Observational study · 2012
Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans
Study of multiple preparations
- International Prostate Symptom Score
- 20.94 ± 8.49 → 8.46 ± 2.78p<0.01
- Urinary flow
- 4.9 ± 2.3 → 9.1 ± 2.5 mL/sp<0.001
- Urinary symptom quality-of-life item
- 4.10 ± 1.01 → 2.53 ± 0.61p<0.001
In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.
More reported outcomes
- Severe urinary symptoms
- 61/150 → 14/150IPSS ≥20. The paper reports 40.7% → 9.3%.
Study notes · methods, sources and limitations
Participants or model 150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.
Design Prospective, within-person comparison of urinary symptoms, quality of life and urine flow before and after adjunctive treatment. All reported denominators below are 150 at each assessment.
Important limitations
- There was no concurrent untreated comparator or single-product arm. The results cover the combination. The tested Veziliut lot and its peptide content remain unclear. The two 150-person publications are part of the same parent program, and participant overlap remains unverified.
Journal of Tropical Science and Technology. 2012;(1):85–93. · Publication record
Performance research in context
- Compound class
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
49 patients: 27 adjunctive Ventfort; 22 controls; ages 52–84, atherosclerosis or senile purpura.
Study methods
Small comparative institute report; allocation, blinding and outcome interpretation require caution
Independent replication
Independent replication not established in this collection
Source access
Report reproduction linked; source language and review scope shown per record
Safety evidence
Short-term reports do not establish long-term safety or equivalence to current products
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Comparison in people · 2021
Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration
Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.
Study notes and original source
Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration
Temporal paravascular Retinalamin injections with or without Cortexin and Ventfort Lingval by electrophoresis · Original journal report
A. V. Derkach, S. V. Trofimova · Vrach. 2021;32(5):85–87.
Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.
Results and tables
Reported findings and study design
Five courses, repeated one to two times per year. The methods list temporal paravascular Retinalamin 5 mg daily for 10 days in both groups. In the combination group, Cortexin and Ventfort Lingval were given by cathodal drug electrophoresis daily for five days, 20 minutes per session at up to 0.1 mA/cm². Active mass for the two electrophoresis preparations was unspecified.
Population or model 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Visual acuity | Retinalamin alone 0.71 ± 0.05 to 0.76 ± 0.04. Combination 0.76 ± 0.05 to 0.88 ± 0.04. | |
| Electroretinogram a-wave amplitude | Retinalamin alone 21.2 ± 1.5 to 28.1 ± 1.7 µV. Combination 21.4 ± 1.5 to 33.9 ± 1.5 µV. | |
| Electroretinogram b-wave amplitude | Retinalamin alone 173.7 ± 8.1 to 222.7 ± 6.6 µV. Combination 172.8 ± 8.6 to 250.0 ± 7.3 µV. |
The combination adds two preparations and a different procedure. The report supplies no treatment-specific estimate for Cortexin or Ventfort Lingval and no between-group confidence intervals.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
- Source reviewed
- Original Russian article, treatment methods and Tables 1 and 2.
Study limitations
- The report gives no randomization or masking method and the groups start with different acuity values. The contribution of each added preparation and electrophoresis cannot be isolated.
- The methods name Retinalamin but also describe Retilin in the adjacent text. The authors leave the mass applied by electrophoresis unspecified.
- The narrative percentages lack clear denominators. The tables contain no between-group p values or confidence intervals. Independent overlap with other retina cohorts is unspecified.
Reviewed 2026-11-16.
Comparison in people · 2013
Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.
Study notes and original source
Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis
Oral vascular, brain, liver and pineal polypeptide preparations added to standard therapy · Conference report · company reproduction
D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.
Results and tables
Reported findings and study design
Moscow, December 2011 to June 2012. Standard treatment alone (514), with Ventfort and Cerluten (319), or with those two plus Svetinorm and Endoluten (416). The Russian methods list two oral capsules each per day for three months for Ventfort, Cerluten and Svetinorm when assigned. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified.
Population or model 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Total cholesterol | 7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4. | Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable. |
| VLDL cholesterol | 1.22 ± 0.06, 0.92 ± 0.07 and 0.87 ± 0.05 mmol/L, respectively. Shared baseline 1.42 ± 0.07. | Both adjunctive groups are marked significant versus standard care. |
| Reported fatigue | 64.0%, 32.3% and 12.9%, respectively. Shared baseline 75.6%. | Only the four-product group is marked significant versus standard care in the fatigue row. |
The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. Symptom assessment and statistical methods are incompletely reported. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
- Source reviewed
- Authors’ conference material, Russian reproduction, PDF pages 8–10, methods and Tables 1–2. English and Russian editions describe the same comparison.
Study limitations
- The authors excluded statin users and people with prior stroke. The comparison provides no individual estimates for Svetinorm or Endoluten.
- Both editions name Svetinorm in the four-product group and outcome tables. The English dosing list instead says Suprefort. The schedule below follows the Russian methods.
- The table gives one shared pretreatment column. Methods of allocation and masking, timing of the reported tables and adverse-event ascertainment are unspecified.
- Table 1 repeats the triglyceride heading with values of unclear identity. The cholesterol, VLDL and first triglyceride rows are legible.
- The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
Reviewed 2026-11-16.
Observational study · 2012
Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans
In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.
Study notes and original source
Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans
Veziliut, Vezugen, Kristagen and Ventfort as named in the paper. Branded oral preparations.
Hoàng Văn Huấn, Phạm Khắc Linh, Nguyễn Như Nghĩa, and colleagues · Journal of Tropical Science and Technology. 2012;(1):85–93.
In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.
Results and tables
Reported findings and study design
Prospective, within-person comparison of urinary symptoms, quality of life and urine flow before and after adjunctive treatment. All reported denominators below are 150 at each assessment.
Population or model 150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.
Dose, route and schedule
The 20-day oral regimen lists Veziliut, Vezugen, Kristagen and Ventfort at 0.2 g each per day. These are amounts of the named products. The paper gives no purified peptide content.
Protocol source ↗ · Original journal PDF, methods and Tables 1–3. Parent program report and Ministry of Defence project citation checked.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| International Prostate Symptom Score | 20.94 ± 8.49 → 8.46 ± 2.78 | p<0.01 |
| Urinary flow | 4.9 ± 2.3 → 9.1 ± 2.5 mL/s | p<0.001 |
| Urinary symptom quality-of-life item | 4.10 ± 1.01 → 2.53 ± 0.61 | p<0.001 |
| Severe urinary symptoms | 61/150 → 14/150 | IPSS ≥20. The paper reports 40.7% → 9.3%. |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.
- Source reviewed
- Original journal PDF, methods and Tables 1–3. Parent program report and Ministry of Defence project citation checked.
Study limitations
- There was no concurrent untreated comparator or single-product arm. The results cover the combination.
- The tested Veziliut lot and its peptide content remain unclear. The two 150-person publications are part of the same parent program, and participant overlap remains unverified.
Reviewed 2026-11-14.
Experiment described in a patent · 2016
Ventfort plus Chonsurid: dental bone-healing method — RU2593817C2
The Ventfort case had higher final density but slightly later reported healing, alongside a larger defect.
Ventfort adjunct case · 22 mm defect: healing at 6.5 months; density 211 HU · One 63-year-old patient
Study notes and original source
Ventfort plus Chonsurid: dental bone-healing method — RU2593817C2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Андрей Константинович Иорданишвили, Антон Анатольевич Сериков, Дмитрий Викторович Балин, Анна Геннадьевна Слугина, Владимир Владимирович Самсонов, Борис Лаврович Макеев, Ирина Борисовна Долгова · RU2593817C2 · patent family 56011738
The Ventfort case had higher final density but slightly later reported healing, alongside a larger defect.
Results and tables
Reported patent results
Reported findings
The Ventfort case had higher final density but slightly later reported healing, alongside a larger defect.
Two dental-cyst examples with Chonsurid; one also received branded Ventfort before surgery.
Population or model Two dental-cyst examples with Chonsurid; one also received branded Ventfort before surgery.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Ventfort adjunct case | 22 mm defect: healing at 6.5 months; density 211 HU | One 63-year-old patient |
| Chonsurid-only example | 14 mm defect: healing at 6 months; density 194 HU | One 64-year-old patient |
| Neutral timing observation | Longer intake reportedly did not further accelerate healing; postoperative or shorter preoperative use lacked a marked benefit | No group sizes or effect estimates supplied |
These selected cases do not establish faster healing. Defect size, different patients, co-treatment and extract identity prevent attribution to Ventfort or a defined vascular peptide.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Two dental-cyst examples with Chonsurid; one also received branded Ventfort before surgery.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The extract brand is not interchangeable with Vasolin, Slavinorm or purified KED, and combined treatment prevents independent attribution.
- These selected cases do not establish faster healing. Defect size, different patients, co-treatment and extract identity prevent attribution to Ventfort or a defined vascular peptide.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Comparison in people · 2006
Ventfort: clinical report on a tissue-derived preparation
The 2005–2006 report describes lipid and capillary-fragility outcomes during 10–15 days of adjunctive care.
Study notes and original source
Ventfort: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes lipid and capillary-fragility outcomes during 10–15 days of adjunctive care.
- Population / setting
- 49 patients: 27 adjunctive Ventfort; 22 controls; ages 52–84, atherosclerosis or senile purpura.
- Source reviewed
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
- The table contains inconsistent sex subtotals. Lipid-table significance is relative to baseline; it does not establish fewer cardiovascular events.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-10-02.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗